Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases
Joint Bone Spine
.
2022 Jan;89(1):105253.
doi: 10.1016/j.jbspin.2021.105253.
Epub 2021 Jul 24.
Authors
Pascal Richette
1
,
Matthieu Allez
2
,
Vincent Descamps
3
,
Lucas Perray
4
,
Simon Pilet
4
,
Augustin Latourte
5
,
Milka Maravic
4
Affiliations
1
Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France. Electronic address: pascal.richette@aphp.fr.
2
Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France.
3
Dermatology department, Bichat Hospital, AP-HP, Paris, France.
4
IQVIA, La Défense, France.
5
Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France.
PMID:
34314887
PMCID:
PMC8305295
DOI:
10.1016/j.jbspin.2021.105253
No abstract available
Keywords:
Biologics; COVID-19; Treatment.
Publication types
Letter
MeSH terms
Biological Products* / therapeutic use
Biological Therapy
COVID-19*
Humans
Prescriptions
SARS-CoV-2
Substances
Biological Products